Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-64.92	-132.07	-88.48	-86.91	-90.87
Depreciation & Amortization	0.45	0.81	0.86	0.8	0.92
Asset Writedown & Restructuring Costs	-	86.91	6.63	-	-
Stock-Based Compensation	12.38	10.86	20.54	15.04	14.06
Other Operating Activities	2.3	2.5	-27.27	4.7	25.09
Change in Accounts Receivable	6.14	-4.88	0.19	0.14	0.15
Change in Accounts Payable	8.45	-4.19	-1.47	0.37	3.66
Change in Unearned Revenue	-3.82	23.93	-	-	-
Change in Other Net Operating Assets	-8.1	-3.94	10.68	-1.7	-5.15
Operating Cash Flow	-47.11	-20.08	-78.33	-67.57	-52.13
Capital Expenditures	-0.11	-0.12	-1.31	-0.61	-0.31
Sale (Purchase) of Intangibles	-0.83	-35.81	-	-	-
Investment in Securities	49.31	-33.84	47.53	13.23	-167.32
Investing Cash Flow	48.37	-69.77	46.22	12.63	-167.63
Long-Term Debt Repaid	-	-	-	-	-11.48
Net Debt Issued (Repaid)	-	-	-	-	-11.48
Issuance of Common Stock	-	80.03	27.63	72.9	239.66
Repurchase of Common Stock	-0.45	-0.41	-0.1	-0.03	-3.12
Other Financing Activities	-5.42	-5.09	-0.83	-	-
Financing Cash Flow	-5.86	74.54	26.71	72.87	225.05
Net Cash Flow	-4.61	-15.31	-5.4	17.93	5.29
Free Cash Flow	-47.22	-20.2	-79.63	-68.17	-52.44
Free Cash Flow Margin	-603.42%	-107.89%	-254.84%	-229.13%	-775.65%
Free Cash Flow Per Share	-0.39	-0.26	-1.14	-1.04	-0.92
Levered Free Cash Flow	-30.63	-59.12	-37.97	-39.31	-28.51
Unlevered Free Cash Flow	-30.63	-59.12	-37.97	-39.31	-28.51
Change in Working Capital	2.67	10.92	9.39	-1.2	-1.34

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q